Product Description
Mechanisms of Action: SV2A Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Epilepsy|Epilepsies, Partial
Phase 2: Epilepsies, Partial